INTENDED FOR UK HEALTHCARE PROFESSIONALS
Fostair® logo (beclometasone/formoterol) Extrafine formulation 100/6 & 200/6
Background
Fostair® logo (beclometasone/formoterol) Extrafine formulation 100/6 & 200/6 - Fostair® NEXThaler® and pMDI devices

Fostair® in Asthma

Fostair is available in the following presentations for maintenance therapy of adult asthma, each delivering 120 inhalations per device.1-4

  • Fostair NEXThaler 100/6
  • Fostair NEXThaler 200/6
  • Fostair pMDI 100/6
  • Fostair pMDI 200/6
Fostair® NEXThaler and pMDI device images for 100/6 & 200/6

Fostair is available in the following presentations for maintenance therapy of adult asthma, each delivering 120 inhalations per device.1-4

  • Fostair NEXThaler 100/6
  • Fostair NEXThaler 200/6
  • Fostair pMDI 100/6
  • Fostair pMDI 200/6
With Fostair pMDI 100/6 and Fostair NEXThaler 100/6 available for use in maintenance and reliever therapy (MART) in adult asthma.1,3
Stepping patients up from Clenil® (beclometasone) to Fostair[[5]]
Device table showing comparison information for Clenil® Modulite® pMDI and Fostair® 100/6 & 200/6

B.D.: Twice daily
Adapted from BTS/SIGN British guideline on the management of asthma 153:2016.5

Comparable efficacy
  • Fostair NEXThaler has demonstrated comparable efficacy to Fostair pMDI across a variety of lung function measures and asthma control1,2
  • Both Fostair pMDI and Fostair NEXThaler are characterised by an extrafine particle size distribution

Fostair‘s extrafine particle size distribution results in a more potent effect than formulations of beclometasone with a non-extrafine particle size distribution3,4

100mcg of extrafine beclometasone in Fostair is equivalent to 250mcg of non-extrafine beclometasone3,4

For additional information to share with your patients who have been prescribed Fostair NEXThaler or Fostair pMDI please visit our Fostair NEXThaler patient and carer site or Fostair pMDI patient and carer site
References:
1. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
2. Fostair NEXThaler 200/6 Summary of Product Characteristics. Chiesi Limited.
3. Fostair pMDI 100/6 Summary of Product Characteristics. Chiesi Limited.
4. Fostair pMDI 200/6 Summary of Product Characteristics. Chiesi Limited.
5. British Thoracic Society and Scottish Intercollegiate Guidelines Network. SIGN 153, British guideline on the management of asthma. September 2016.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.

Disclaimer

The purpose of this section of the website is to provide UK healthcare professionals with accurate and relevant information on Chiesi Limited respiratory products.

The contents of this area of the website are intended solely for the use of UK healthcare professionals. If you are NOT a UK healthcare professional, please exit this section of the website.

YES I AM

a UK healthcare professional

NO I'M NOT

a UK healthcare professional

UK-RES-1900858 Jun 2019